AU2008299703C1 - Process for the preparation of a RAF kinase inhibitor and intermediates for use in the process - Google Patents

Process for the preparation of a RAF kinase inhibitor and intermediates for use in the process Download PDF

Info

Publication number
AU2008299703C1
AU2008299703C1 AU2008299703A AU2008299703A AU2008299703C1 AU 2008299703 C1 AU2008299703 C1 AU 2008299703C1 AU 2008299703 A AU2008299703 A AU 2008299703A AU 2008299703 A AU2008299703 A AU 2008299703A AU 2008299703 C1 AU2008299703 C1 AU 2008299703C1
Authority
AU
Australia
Prior art keywords
derivative
sorafenib
trifluoromethyl
compound
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008299703A
Other languages
English (en)
Other versions
AU2008299703A1 (en
AU2008299703B2 (en
Inventor
Sandip Chikhalikar
Maruti Ghagare
Rajendra Narayanrao Kankan
Dharmaraj Ramachandra Rao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cipla Ltd
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cipla Ltd filed Critical Cipla Ltd
Publication of AU2008299703A1 publication Critical patent/AU2008299703A1/en
Application granted granted Critical
Publication of AU2008299703B2 publication Critical patent/AU2008299703B2/en
Publication of AU2008299703C1 publication Critical patent/AU2008299703C1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/58—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/12—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
    • C07C233/15—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/30—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by halogen atoms, or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/32—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms
    • C07C275/34—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms having nitrogen atoms of urea groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/64—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups singly-bound to oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2008299703A 2007-09-10 2008-09-10 Process for the preparation of a RAF kinase inhibitor and intermediates for use in the process Ceased AU2008299703C1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN1733MU2007 2007-09-10
IN1734/MUM/2007 2007-09-10
IN1733/MUM/2007 2007-09-10
IN1734MU2007 2007-09-10
PCT/GB2008/003048 WO2009034308A2 (en) 2007-09-10 2008-09-10 Process for the preparation of a raf kinase inhibitor and intermediates for use in the process

Publications (3)

Publication Number Publication Date
AU2008299703A1 AU2008299703A1 (en) 2009-03-19
AU2008299703B2 AU2008299703B2 (en) 2013-06-20
AU2008299703C1 true AU2008299703C1 (en) 2013-09-05

Family

ID=40351766

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008299703A Ceased AU2008299703C1 (en) 2007-09-10 2008-09-10 Process for the preparation of a RAF kinase inhibitor and intermediates for use in the process

Country Status (9)

Country Link
US (1) US8445687B2 (enExample)
EP (1) EP2195286A2 (enExample)
JP (1) JP5438680B2 (enExample)
KR (1) KR101553211B1 (enExample)
AU (1) AU2008299703C1 (enExample)
CA (1) CA2698795C (enExample)
NZ (1) NZ583790A (enExample)
WO (1) WO2009034308A2 (enExample)
ZA (1) ZA201001935B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2359244C (en) 1999-01-13 2013-10-08 Bayer Healthcare Llc .omega.-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP2324825A1 (en) 2002-02-11 2011-05-25 Bayer Healthcare LLC Aryl ureas with angiogenesis inhibiting activity
DE602004007382T2 (de) 2003-05-20 2008-04-17 Bayer Pharmaceuticals Corp., West Haven Diaryl-harnstoffe für durch pdgfr vermittelte krankheiten
KR101553211B1 (ko) 2007-09-10 2015-09-15 씨아이피엘에이 엘티디. Ｒａｆ 키나아제 저해제의 제조방법 및 상기 제조방법에 사용되는 중간체
WO2010026124A1 (en) 2008-09-02 2010-03-11 Novartis Ag Picolinamide derivatives as kinase inhibitors
EP2480534A1 (en) 2009-09-24 2012-08-01 Ranbaxy Laboratories Limited Process for the preparation of sorafenib tosylate
US8604208B2 (en) 2009-09-24 2013-12-10 Ranbaxy Laboratories Limited Polymorphs of sorafenib acid addition salts
WO2011058522A1 (en) 2009-11-12 2011-05-19 Ranbaxy Laboratories Limited Sorafenib ethylsulfonate salt, process for preparation and use
EP2528899B1 (en) 2010-01-29 2014-10-15 Ranbaxy Laboratories Limited Sorafenib dimethyl sulphoxide solvate
CN102190616B (zh) * 2010-03-18 2015-07-29 苏州泽璟生物制药有限公司 一种氘代的ω-二苯基脲的合成及生产的方法和工艺
SG191309A1 (en) * 2011-01-18 2013-07-31 Glaxo Group Ltd Process for the preparation of retigabine
CN102485714B (zh) * 2011-10-09 2013-07-24 连云港盛和生物科技有限公司 一种羰基化合成索拉菲尼的方法
PE20150194A1 (es) 2012-05-21 2015-02-08 Novartis Ag Novedosas n-piridinil amidas ciclicas sustituidas como inhibidores de quinasa
CN103508961B (zh) * 2012-06-26 2015-07-22 中美冠科生物技术（太仓）有限公司 抗肿瘤药物
CN103408488A (zh) * 2013-08-13 2013-11-27 张家港威胜生物医药有限公司 一种索拉非尼的优化合成方法
JP6612232B2 (ja) 2013-08-28 2019-11-27 クラウン バイオサイエンス インコーポレイテッド（タイカン） 対象のマルチキナーゼ阻害剤に対する応答性を予測する遺伝子発現シグネチャ、及びその使用
CN104761492A (zh) * 2014-01-03 2015-07-08 正大天晴药业集团股份有限公司 对甲苯磺酸索拉非尼的晶型及其制备方法
CN105481764A (zh) * 2014-09-16 2016-04-13 重庆圣华曦药业股份有限公司 一种索拉非尼对甲苯磺酸盐的制备方法
CN105399668B (zh) * 2015-12-29 2018-11-16 开封制药(集团)有限公司 一种“一锅法”制备索拉菲尼的方法
CN105801475B (zh) * 2016-04-25 2018-01-12 华润双鹤利民药业（济南）有限公司 一种甲苯磺酸索拉非尼的制备方法
CN109796400B (zh) * 2017-11-16 2022-07-29 四川科伦药物研究院有限公司 一种甲苯磺酸索拉菲尼晶型及其制备方法
CN108623521B (zh) * 2018-03-22 2020-09-04 盐城师范学院 一种乐伐替尼的制备方法
CN108558747A (zh) * 2018-03-31 2018-09-21 山东罗欣药业集团恒欣药业有限公司 一种瑞戈非尼的制备方法
CN108440403A (zh) * 2018-03-31 2018-08-24 山东罗欣药业集团恒欣药业有限公司 一种瑞戈非尼的制备方法
CN108276327A (zh) * 2018-03-31 2018-07-13 山东罗欣药业集团恒欣药业有限公司 一种索拉非尼的制备方法
CN108276328A (zh) * 2018-03-31 2018-07-13 山东罗欣药业集团恒欣药业有限公司 一种索拉非尼的制备方法
CN108586329A (zh) * 2018-03-31 2018-09-28 山东罗欣药业集团恒欣药业有限公司 一种索拉非尼的合成方法
CN108341770A (zh) * 2018-03-31 2018-07-31 山东罗欣药业集团恒欣药业有限公司 一种索拉非尼化合物的制备方法
CN108586330A (zh) * 2018-04-18 2018-09-28 日照市普达医药科技有限公司 一种治疗肿瘤药物的制备方法及其应用
CN114144410A (zh) 2019-07-19 2022-03-04 阿纳格纳斯生物技术股份有限公司 多芳基脲衍生物及其在治疗肌肉疾病中的用途
EP4029501A1 (en) 2021-01-19 2022-07-20 Anagenesis Biotechnologies Combination of polyaromatic urea derivatives and glucocorticoid or hdac inhibitor for the treatment of diseases or conditions associated with muscle cells and/or satellite cells

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000042012A1 (en) * 1999-01-13 2000-07-20 Bayer Corporation φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
WO2000041698A1 (en) * 1999-01-13 2000-07-20 Bayer Corporation φ-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
WO2005121147A1 (en) * 2004-06-03 2005-12-22 Bayer Pharmaceuticals Corporation Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
WO2006034796A1 (en) * 2004-09-29 2006-04-06 Bayer Healthcare Ag Process for the preparation of 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-n-methylpyridine-2-carboxamide
WO2007064931A2 (en) * 2005-12-02 2007-06-07 Bayer Healthcare Llc Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL123536C (enExample) 1963-07-09
FR1484461A (fr) 1965-06-25 1967-06-09 Grace W R & Co Compositions herbicides
CH50468A4 (enExample) 1968-01-12 1970-06-30
CH490005A (de) * 1968-02-06 1970-05-15 Ciba Geigy Schädlingsbekämpfungsmittel
BE788983A (fr) * 1971-09-22 1973-01-15 Rolland Sa A 3-trifluoromethylanilides
US5541224A (en) * 1994-03-14 1996-07-30 Eli Lilly And Company Carbanilide anticoccidials
PT1690853E (pt) * 1999-01-13 2010-04-23 Bayer Healthcare Llc Difenilureias substituídas com w-carboxiarilo como inibidores de raf-quinase
US6242385B1 (en) * 2000-02-28 2001-06-05 Uniroyal Chemical Company, Inc. Enhancement of seed/fruit/nut yields from flowering plants
US7528124B2 (en) 2003-08-28 2009-05-05 Taisho Pharmaceutical Co., Ltd. 1,3-dihydro-2H-indol-2-one derivative
TW200730503A (en) 2005-10-21 2007-08-16 Daiichi Seiyaku Co Tricyclic compound
KR101553211B1 (ko) 2007-09-10 2015-09-15 씨아이피엘에이 엘티디. Ｒａｆ 키나아제 저해제의 제조방법 및 상기 제조방법에 사용되는 중간체

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000042012A1 (en) * 1999-01-13 2000-07-20 Bayer Corporation φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
WO2000041698A1 (en) * 1999-01-13 2000-07-20 Bayer Corporation φ-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
WO2005121147A1 (en) * 2004-06-03 2005-12-22 Bayer Pharmaceuticals Corporation Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
WO2006034796A1 (en) * 2004-09-29 2006-04-06 Bayer Healthcare Ag Process for the preparation of 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-n-methylpyridine-2-carboxamide
WO2007064931A2 (en) * 2005-12-02 2007-06-07 Bayer Healthcare Llc Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
VAUTHEY, I. ET AL: Tetrahedron Letters, Vol. 41, No. 33, 2000, pages 6347-6350 *

Also Published As

Publication number Publication date
ZA201001935B (en) 2010-11-24
CA2698795C (en) 2016-04-19
JP2010539076A (ja) 2010-12-16
EP2195286A2 (en) 2010-06-16
AU2008299703A1 (en) 2009-03-19
KR20100074175A (ko) 2010-07-01
WO2009034308A2 (en) 2009-03-19
NZ583790A (en) 2012-04-27
US8445687B2 (en) 2013-05-21
CA2698795A1 (en) 2009-03-19
KR101553211B1 (ko) 2015-09-15
US20100311980A1 (en) 2010-12-09
WO2009034308A3 (en) 2009-07-16
JP5438680B2 (ja) 2014-03-12
AU2008299703B2 (en) 2013-06-20

Similar Documents

Publication Publication Date Title
AU2008299703B2 (en) Process for the preparation of a RAF kinase inhibitor and intermediates for use in the process
AU694465B2 (en) Anthranilic acid derivative
TWI382973B (zh) 方法
SG174069A1 (en) 4-substituted phenoxyphenylacetic acid derivatives
JPH0733729A (ja) Ｎ−シアノ−ｎ′−置換−アリールカルボキシイミダミド化合物の製造法
WO2009054004A2 (en) Process for the preparation of sorafenib
HUE030696T2 (en) Process for the preparation of dabigatran etexilate and its intermediates
US9533971B2 (en) Process for the synthesis of dabigatran and its intermediates
GB2106499A (en) Method for making benzoylphenylureas
EP2170872B1 (en) Process for the preparation of the n-(2-chloro-4-methyl-3-thienyl)-1h- benzimidazol-2-amine hydrochloride and intermediates thereof
JPS5917106B2 (ja) Ｎ−クロルホルミル−ｎ，ｎ’−二置換尿素誘導体の製法
KR100519420B1 (ko) 헤테로아릴카복실아미드및에스테르의제조방법
US4137253A (en) Preparation of chloroformates having terminal acrylic or methacrylic groups
US5386057A (en) Process for the preparation of acyl isocyanates
US6087506A (en) Preparation of hetero arylcarboxamides
US10752585B2 (en) Process for the preparation of Zafirlukast and analogs thereof
Takei et al. The Preparation of Iminosulfonic Acid Derivatives by Means of Sulfinamides and N-Bromosuccinimide
JPS607987B2 (ja) ヒダントイン誘導体
CN115246791B (zh) 一种合成6-三氟甲基尿嘧啶的方法及其中间体
Patra et al. DCPDC-Mediated Facile Amide-Bond Formation of Non-Nucleophilic and Hindered Amines
JP2815476B2 (ja) ベンゼンスルホンアミド化合物の改良された製造法
JPH0789926A (ja) 尿素類又はセミカルバジド類の製造法
WO2019160037A1 (ja) 酸ハロゲン化物による化合物の製造方法
JPS5865273A (ja) カルバモイルアミノマレイミド類およびその製法
JPS62169758A (ja) アルコキシカルボニルイソシアネ−ト類の製造方法

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 23 MAY 2013 .

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 23 MAY 2013

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired